Source comparison
TB-500 Studied Scar Healing: Research vs Clinical Comparison
Equine dermal wound (2018) 7.5mg SC twice weekly × 4 weeks Histological scar analysis at 8 weeks 42% reduction vs control 31% increase in organized fiber deposition Most robust preclinical data. Dosing translates to ~4–5mg in human equivalent Human venous ulce
This comparison does not assign a generated winner or score.
- Equine dermal wound (2018)
- 7.5mg SC twice weekly × 4 weeks
- Histological scar analysis at 8 weeks
- 42% reduction vs control
- 31% increase in organized fiber deposition
- Most robust preclinical data. Dosing translates to ~4–5mg in human equivalent
- Human venous ulcer pilot (2020)
- 2mg SC twice weekly × 6 weeks
- Ultrasound elastography at 12 weeks
- 34% less fibrosis
- Improved tissue compliance (not quantified)
- Lower dose than animal studies but still significant. Suggests threshold around 2–3mg
- Rat full-thickness wound (2016)
- 1mg SC daily × 14 days
- Tensile strength testing at day 21
- Not measured
- 28% improvement in tensile strength
- Daily dosing produced similar results to twice-weekly higher doses. Frequency may compensate for lower per-dose amount
- In vitro fibroblast culture (2019)
- 10 ng/mL culture media
- Gene expression analysis (qPCR)
- N/A. Cell culture
- 2.4-fold increase in beta-actin mRNA
- Confirms mechanism. Effect is transcriptional, not just extracellular signaling